18.207.157.152
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Industry News

Visus Therapeutics expands clinical advisory board with appointment of renowned ophthalmologists

Posted on October 26, 2020

Visus Therapeutics Inc, a clinical-stage company in pursuit of developing the world’s first presbyopia-correcting eye drop with the potential to last a minimum of eight hours, today announced the appointments of prominent ophthalmologists Marguerite McDonald, MD, Neda Shamie, MD, William Trattler, MD, and Lawrence Woodard, MD, to its clinical advisory board. Drs McDonald, Shamie, Trattler and Woodard will lend their decades of experience in clinical practice and pharmaceutical trials to provide strategic guidance related to Visus’ clinical development program for BRIMOCHOL, an investigational eye drop designed to restore the loss of near vision associated with presbyopia. The clinical advisory board is led by industry veteran Eric Donnenfeld, MD, founding partner of Ophthalmic Consultants of Long Island and Connecticut and Clinical Professor of Ophthalmology at New York University Medical Center.

“We are honored to welcome this renowned group of ophthalmologists to our clinical advisory board at this pivotal time for Visus, specifically as we advance into Phase 2 clinical studies with our lead candidate, BRIMOCHOL,” said Ben Bergo, co-founder, president and chief executive officer of Visus Therapeutics. “Each board member’s individual expertise as well as their collective knowledge of the industry will be invaluable in our endeavor to develop the world’s first presbyopia-correcting eye drop that has the potential to last a minimum of eight hours. We look forward to collaborating with this talented team of experts as we continue to move our clinical development program forward.”

Dr. McDonald is a fellowship-trained cornea specialist who practices at Ophthalmic Consultants of Long Island. She is also a Clinical Professor of Ophthalmology at New York University in Manhattan and a Clinical Professor of Ophthalmology at Tulane University Medical School in New Orleans. Her pioneering work in refractive surgery included development and performance of the world’s first excimer laser refractive procedure in patients in 1988. Dr. McDonald serves on numerous editorial boards of clinical and scientific journals and is an active member of multiple national and international professional societies, having served as the first female President of the American Society of Cataract and Refractive Surgery (ASCRS) and the first female President of the International Society of Refractive Surgery of the American Academy of Ophthalmology.

Read the full press release here.

-Advertisement-
Related Articles
Newly formed Ophthalmology Foundation will improve global eye care through education
Mar 17, 2021
Iridex enters into strategic collaboration with Topcon Corporation
Mar 02, 2021
Allergan submits new drug application for investigational treatment of presbyopia
Feb 25, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-